Clinical trial
Triple-Therapy With PegInterferon α-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon α + Ribavirin
NCT01585584 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Triple-Therapy With PegInterferon α-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon α + Ribavirin
- Lead sponsor
- University of Calgary
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2012
- Completion date
- July 31, 2015
- Enrollment
- 11 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.